Managing an Illness Without a Cure
Let's be clear from the outset: as of 2025, there is no proven cure for myalgic encephalomyelitis/chronic fatigue syndrome. No pill, programme, supplement or therapy has been shown in rigorous clinical trials to reliably reverse the illness. That is a hard truth, and it deserves to be stated plainly rather than softened. What medicine can offer is something less dramatic but genuinely valuable — the careful management of individual symptoms, the reduction of harm from the illness itself, and a realistic path toward a more stable life.
The goal, in other words, is not recovery on demand. It is stabilisation: reducing the frequency and severity of crashes, staying within your energy envelope, and protecting whatever function you currently have. For many patients, achieving even that modest aim transforms day-to-day existence. It requires a clinician who understands ME/CFS, a willingness to experiment slowly and carefully, and — crucially — a rejection of the "push through it" instinct that makes this illness worse.
Treatment is always individual. Two people with identical diagnoses may respond completely differently to the same intervention. What follows is a guide to what the current evidence supports; none of it replaces a conversation with a qualified clinician who knows your case.
Sleep: Treating the Symptom, Not Just the Fatigue
Unrefreshing sleep is one of the most consistent features of ME/CFS — the kind of sleep that leaves you feeling no better in the morning than when you went to bed. It is not ordinary tiredness, and it is not resolved by simply sleeping longer. Research suggests genuine abnormalities in sleep architecture may be involved, though this remains an active area of investigation.
Clinicians often begin with sleep hygiene — consistent sleep and wake times, limiting caffeine, minimising light and noise at night. These measures are low-risk and sometimes help at the margins. Where sleep disturbance is severe, low-dose medications may be considered: certain tricyclic antidepressants at sub-antidepressant doses, such as low-dose amitriptyline, are sometimes prescribed to improve sleep quality and reduce pain simultaneously. Melatonin has a modest evidence base for correcting circadian disruption. None of these are cures for the underlying problem, and all should be introduced carefully, since people with ME/CFS can be unusually sensitive to medications.
What the evidence does not support is using stimulants or simply ignoring poor sleep in favour of activity programmes. Treating sleep as a symptom in its own right — rather than a side effect of psychological distress — is one of the clearest shifts in how good clinicians now approach ME/CFS.
But it has not yet translated into a proven cure.
Pain: A Many-Layered Problem
Pain in ME/CFS is real, measurable, and often under-treated. It can manifest as widespread muscle aching, joint pain without swelling, headaches, and hypersensitivity to touch or temperature. The mechanisms are not fully understood, but evidence points toward central sensitisation — a state in which the nervous system amplifies pain signals — rather than tissue damage in the conventional sense.
Low-dose tricyclics can help here, as noted above. Some patients find benefit from low-dose naltrexone, an approach with a small but growing body of supportive research, though it is not yet a standard recommendation and larger trials are needed. Over-the-counter analgesics offer some relief for episodic pain, though regular high-dose use carries its own risks. Anti-inflammatory medications are sometimes used, though evidence for their efficacy in ME/CFS specifically is limited.
What clinicians and patients together must avoid is the assumption that if one pain strategy fails, the condition is untreatable. Pain management in ME/CFS is iterative — a process of careful trial, honest assessment, and adjustment. Consulting a clinician familiar with conditions involving central sensitisation, such as a pain specialist, can open options that a general practitioner alone may not have explored.
Orthostatic Intolerance and POTS
A significant proportion of ME/CFS patients experience orthostatic intolerance — dizziness, lightheadedness, rapid heart rate, or near-fainting when sitting or standing upright. In some, this meets the criteria for postural orthostatic tachycardia syndrome (POTS), a condition in which heart rate increases abnormally on standing. Orthostatic intolerance is increasingly recognised as a genuine biological feature of ME/CFS, not an incidental complaint.
Management begins with non-pharmacological measures: increasing fluid and salt intake to boost blood volume, wearing compression garments on the legs, and learning to rise slowly from sitting or lying positions. Elevating the head of the bed slightly at night can reduce early-morning symptoms. These steps help many patients meaningfully, and the evidence for their safety is solid.
When conservative measures fall short, medications including fludrocortisone (which helps retain salt and fluid), low-dose beta-blockers, or ivabradine are sometimes considered. The evidence base for these in ME/CFS-associated POTS is largely drawn from POTS research more broadly, and their use should be supervised by a clinician experienced in autonomic disorders. Research groups including those at Griffith University's National Centre for Neuroimmunology and Emerging Diseases (NCNED) in Queensland, Australia, have been investigating the biological mechanisms underlying these cardiovascular features, work that may eventually inform more targeted interventions.
Cognitive Symptoms and the Contested Territory of CBT
Brain fog — the difficulty concentrating, the gaps in memory, the sense of thinking through cotton wool — is among the most disabling aspects of ME/CFS for many people. It is a biological symptom of a biological illness, not a sign of depression or poor motivation, and it deserves the same seriousness as any other feature of the disease.
Currently, there are no medications with strong evidence specifically for ME/CFS-related cognitive impairment, though some patients report modest benefits from low-dose CNS stimulants prescribed cautiously by their clinician. Pacing — the strategic management of cognitive as well as physical effort — remains one of the most practically important tools. Mental activity can trigger post-exertional malaise just as surely as physical activity; protecting cognitive reserves is part of staying within your energy envelope.
Cognitive behavioural therapy (CBT) deserves an honest mention here. CBT was for many years prescribed as a primary treatment for ME/CFS, based on a model that framed the illness as perpetuated by unhelpful beliefs and deconditioning. The UK's National Institute for Health and Care Excellence reviewed the evidence comprehensively and, in its updated 2021 guidance, withdrew the recommendation of CBT as a treatment for ME/CFS itself. CBT may still have a supportive role — helping patients cope with the psychological burden of a serious chronic illness, or managing comorbid anxiety — but it should not be presented as curative, and it does not address the underlying biology of the condition. Similarly, the 2021 NICE guidance no longer recommends graded exercise therapy (GET) as a treatment, given evidence that it can worsen symptoms in many patients.
A Word on Unproven Treatments
The absence of a cure creates fertile ground for expensive, unproven, and sometimes harmful "miracle" treatments. Patients with ME/CFS — often desperate, often dismissed by the medical system — are understandably vulnerable to these claims. Online forums, social media, and wellness marketing are full of protocols, supplements, and therapies promoted with patient testimonials but without rigorous evidence.
Patient-centred organisations and resources — among them Health Rising and Phoenix Rising — provide community knowledge and flag both promising research and unsubstantiated claims. They are useful, but they are not a substitute for clinical guidance, and even well-intentioned community recommendations can mislead. Before committing significant money or effort to any unproven treatment, ask whether it has been tested in a peer-reviewed clinical trial, and discuss it with a clinician who will give you a straight answer.
The honest position is this: the science of ME/CFS is advancing, the biological underpinnings are becoming clearer, and treatments tied to those mechanisms are in development. That progress is real. But it has not yet translated into a proven cure. In the meantime, the most evidence-supported path is symptom-by-symptom management, careful pacing, a clinician who takes the illness seriously, and protection against both overexertion and exploitation.
People & places referenced
Griffith University / NCNED
Queensland, Australia
research centre investigating biological mechanisms of ME/CFS, including cardiovascular and neuroimmune features
Health Rising
patient-focused website tracking ME/CFS research and management strategies
Phoenix Rising
patient community forum and information resource for ME/CFS
NICE
UK National Institute for Health and Care Excellence; issues clinical guidelines including 2021 ME/CFS update
This article is for general information only. If you are concerned about your symptoms, please consult a qualified clinician for personal medical advice.